Protein expression profiles and clinicopathologic characteristics associate with gastric cancer survival

Wei Li1,2, Yan Chen1, Xuan Sun1, Jupeng Yang1, David Y. Zhang3, Daguang Wang1* and Jian Suo1,2*

Abstract
Background: Prognosis remains one of most crucial determinants of gastric cancer (GC) treatment, but current methods do not predict prognosis accurately. Identification of additional biomarkers is urgently required to identify patients at risk of poor prognoses.

Methods: Tissue microarrays were used to measure expression of nine GC-associated proteins in GC tissue and normal gastric tissue samples. Hierarchical cluster analysis of microarray data and feature selection for factors associated with survival were performed. Based on these data, prognostic scoring models were established to predict clinical outcomes. Finally, ingenuity pathway analysis (IPA) was used to identify a biological GC network.

Results: Eight proteins were upregulated in GC tissues versus normal gastric tissues. Hierarchical cluster analysis and feature selection showed that overall survival was worse in cyclin dependent kinase (CDK)2, Akt1, X-linked inhibitor of apoptosis protein (XIAP), Notch4, and phosphorylated (p)-protein kinase C (PKC) α/β2 immunopositive patients than in patients that were immunonegative for these proteins. Risk score models based on these five proteins and clinicopathological characteristics were established to determine prognoses of GC patients. These proteins were found to be involved in cancer related-signaling pathways and upstream regulators were identified.

Conclusion: This study identified proteins that can be used as clinical biomarkers and established a risk score model based on these proteins and clinicopathological characteristics to assess GC prognosis.

Keywords: Gastric cancer, Protein expression profiling, Tissue microarray, Immunohistochemistry, Pathway
urgent need for additional biomarkers to identify patients at risk of poor outcomes or recurrence.

GC is a heterogeneous disease, and its initiation and progression are influenced strongly by genetic and environmental factors [14]. Presently, many candidate gene products, such as MUC1, CEA, p53, p16, and E-cadherin, have been suggested to predict the survival of patients with GC [15–19]. Although there has been much investigation of the genetic factors that predict survival, few genetic alterations have been used in GC diagnosis. Recently, it has become possible to conduct large-scale molecular studies on formalin-fixed tissue samples with tissue microarrays and immunohistochemistry. Such large-scale studies have involved numerous markers and cases. For example, a large-scale cluster analysis showed that multiple markers correlated significantly with patient survival [20, 21]. Therefore, tissue microarrays and immunohistochemistry may be a practical method for routine testing and validation studies.

In a previous study, we screened for GC-associated signaling proteins using protein pathway arrays (PPAs) and found that 22 proteins, or phosphorylated (p)-protein forms, were differentially expressed between cancer and normal tissues. Of those 22 proteins, the following 9 were upregulated in GC tissues [1]: proliferating cell nuclear antigen (PCNA), Notch4, cyclin-dependent kinase (CDK)4, CDK6, X-linked inhibitor of apoptosis protein (XIAP), p-protein kinase C (PKC)α/βII, Akt, β-catenin, and p-PKCα. In this study, we aimed to verify overexpression of these proteins in GC using tissue microarrays and immunohistochemistry. We also analyzed survival characteristics to establish prognostic scoring models to improve clinical outcome predictions.

**Materials and methods**

**Patients and tissue samples**

This study included 121 surgically resected primary GC samples collected from patients who underwent D2 gastrectomy over a period of 5 years, between January of 2006 and December of 2012, and 30 normal gastric samples from patients who underwent gastrectomy for non-cancer diseases. Two pathologists confirmed the histological diagnoses and tumor-node-metastasis (TNM) staging of the collected tissues. Clinicopathological characteristics of the GC patients, including gender, age, tumor size, tumor location, histologic differentiation, vascular or lymphatic invasion, and tumor stage, were obtained by reviewing medical charts and pathology records (Table 1). None of the patients received preoperative chemotherapy or radiotherapy. Patients were followed-up from the date of surgery for a period of 6–119 months (mean, 55 months) and clinical outcomes were recorded. Survival time was calculated from the date of surgery to the date of death or the last day of follow-up. The majority of the patients died of the cancer. Cases lost to follow-up were not included in our survival analysis. The Institution Ethical Review Board of The First Hospital of Jilin University approved this study, and all of the patients provided informed consent.

| Clinicopathological characteristics | Patients N = 121 (%) |
|------------------------------------|---------------------|
| **Age (years)**                    |                     |
| ≤ 60                               | 57 (47.1)           |
| > 60                               | 64 (52.9)           |
| **Gender**                         |                     |
| Male                               | 91 (75.2)           |
| Female                             | 30 (24.8)           |
| **Tumor location**                 |                     |
| Lower third                        | 85 (70.2)           |
| Middle third                       | 23 (19.0)           |
| Upper third                        | 13 (10.8)           |
| **Tumor size (cm)**                |                     |
| ≤ 5                                | 94 (77.7)           |
| > 5                                | 27 (22.3)           |
| **Histologic differentiation**     |                     |
| Moderate                           | 38 (31.4)           |
| Poor                               | 83 (68.6)           |
| **Vascular/lymphatic invasion**    |                     |
| Absent                             | 37 (30.6)           |
| Present                            | 84 (69.4)           |
| **T stage**                        |                     |
| T1                                 | 7 (5.8)             |
| T2                                 | 29 (24.0)           |
| T3                                 | 84 (69.4)           |
| T4                                 | 1 (0.8)             |
| **N stage**                        |                     |
| N0                                 | 35 (29.0)           |
| N1                                 | 45 (37.1)           |
| N2                                 | 29 (24.0)           |
| N3                                 | 12 (9.9)            |
| **TNM stage**                      |                     |
| I                                  | 19 (15.7)           |
| II                                 | 27 (22.4)           |
| III                                | 62 (51.2)           |
| IV                                 | 13 (10.7)           |

---

*a* Tumor size measured in greatest transverse diameter (cm)  
*b* TNM staging was performed according to the American Joint Committee on Cancer. No patient had metastasis to distant organs (M0)
Tissue microarrays
Tissue microarrays were prepared as previously described [22]. Briefly, whole sections of individual donor tissue blocks, which were stained with hematoxylin and eosin (H&E), were used to select tumor areas for tissue microarray cores. Three cylinders of tissues (0.6 mm in diameter) were punched from each sample and re-embedded in a recipient paraffin block at predetermined positions. Multiple 4-µm-thick sections were cut from each tissue array block and mounted on microscope slides.

Immunohistochemistry
Sections on tissue microarray slides were dewaxed in xylene and then rehydrated in a series of graded alcohols. Antigen retrieval was performed by autoclaving the sections in citrate buffer (pH 6.0) for 2 min and then cooling them in dH2O. Then, the sections were immersed in 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 15 min to block endogenous peroxidase activity. Non-specific binding was then blocked in 10% normal goat serum at room temperature for 10 min. Subsequently, the sections were incubated with primary antibodies (Table 2) at 4 °C overnight in a moist chamber. After washing with PBS, the sections were incubated with secondary antibodies for 1 h at room temperature. The sections were stained with 3,3-diaminobenzidine and counterstained with Harris hematoxylin, dehydrated, and mounted. Immunoreactivity was evaluated microscopically by two pathologists. Protein staining was graded according to a previous study [23]: 0, negative, − (no cells stained); 1, weakly positive, + (<10% of cells stained); 2, moderately positive < ++ (10–50% of cells stained); or 3, strongly positive, +++ (>50% cells stained).

Cluster analysis
Hierarchical cluster analysis was conducted in the Cluster program (complete linkage clustering) [24]. Clustering analysis results were displayed in TreeView software [25]. Expression data were graded as follows: −3, negative staining; 1, weak positive staining; 2, moderately positive staining; and 3, strongly positive staining.

Signaling network analysis
To visualize the interactions and upstream regulators of differentially expressed proteins, pathway and network analyses were carried out in Ingenuity Pathway Analysis version 9.0 (IPA), a protein-gene and protein–protein interaction analysis program.

Statistical analysis
Chi-square test and Fisher’s exact (two-sided) tests were used to determine associations between protein expression status and clinicopathological variables. Kaplan–Meier survival curves were created, and differences between the curves were examined by log-rank testing. Cox proportional hazard regression analysis was used to determine independent prognostic factors. Principal component analysis (PCA) was performed to establish a survival prediction model for GC patients. Additionally, the Kaiser–Meyer–Olkin measure and Bartlett’s test of sphericity were used to ensure appropriate extraction factor analysis. To determine the optimal prognosis prediction model, receiver operating characteristic (ROC) curve analysis was applied to principal components (PCs), and the area under the curves (AUCs) were calculated. All analyses were performed in SPSS 17.0 (SPSS Inc, Chicago, IL). A p value < 0.05 was considered to be statistically significant.

Results
Protein expression profiling in GC and normal tissues
The immunohistochemistry results for the nine evaluated proteins are shown in Fig. 1 and summarized in Table 3. Notably, p-PKCα was expressed in 97.5% (117/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 46, 59, and 12 cases, respectively. Meanwhile, p-PKCα was expressed in 66.7% (20/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 10, 19, and 0 cases, respectively. p-PKCα/β2 was expressed in 82.6% (100/121) of the GC cases; weakly positive, moderately positive, and strongly positive expression was seen in 59, 37, and 4 cases, respectively. p-PKCα/β2 was expressed in 66.7% (20/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 10, 19, and 0 cases, respectively. p-PKCα/β2 was expressed in 82.6% (100/121) of the GC cases; weakly positive, moderately positive, and strongly positive expression was seen in 59, 37, and 4 cases, respectively. The immunohistochemistry results for the nine evaluated proteins are shown in Fig. 1 and summarized in Table 3. Notably, p-PKCα was expressed in 97.5% (117/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 46, 59, and 12 cases, respectively. Meanwhile, p-PKCα was expressed in 66.7% (20/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 10, 19, and 0 cases, respectively. p-PKCα/β2 was expressed in 82.6% (100/121) of the GC cases; weakly positive, moderately positive, and strongly positive expression was seen in 59, 37, and 4 cases, respectively. p-PKCα/β2 was expressed in 66.7% (20/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 10, 19, and 0 cases, respectively.
Fig. 1 Protein expression detected by immunohistochemistry
Table 3 Expression of nine GC-associated proteins in GC and normal tissues detected by immunohistochemistry

| Protein          | GC (N = 121) No. (%) of patients | Normal gastric tissues (N = 30) No. (%) of patients | p value |
|------------------|---------------------------------|---------------------------------------------------|---------|
|                  | − (3.3)                         | + (38.0)                                          | +++ (59.8) | + (12.9) | − (1.3) | 0 (0) | <0.001 |
| p-PKCα           | 4 (3.3)                         | 46 (38.0)                                         | 59 (48.8) | 12 (9.9) | 10 (33.3) | 19 (63.3) | 1 (3.3) | 0 (0) | <0.007 |
| p-PKCα/β2        | 21 (17.4)                       | 59 (48.8)                                         | 37 (30.6) | 4 (3.3) | 17 (56.7) | 13 (43.3) | 0 (0) | 0 (0) | <0.001 |
| Akt1             | 22 (18.2)                       | 73 (60.3)                                         | 20 (16.5) | 6 (5.0) | 20 (66.7) | 10 (33.3) | 0 (0) | 0 (0) | <0.001 |
| CDK6             | 46 (38.0)                       | 68 (56.2)                                         | 4 (3.3) | 3 (2.5) | 5 (17.7) | 25 (83.3) | 0 (0) | 0 (0) | 0.022 |
| Notch4           | 6 (5.0)                         | 64 (52.9)                                         | 48 (39.7) | 3 (2.5) | 8 (26.7) | 22 (73.3) | 0 (0) | 0 (0) | <0.001 |
| β-Catenin        | 4 (3.3)                         | 96 (79.3)                                         | 21 (17.4) | 0 (0) | 2 (6.7) | 27 (90.0) | 1 (3.3) | 0 (0) | 0.119 |
| CDK2             | 53 (43.8)                       | 55 (45.5)                                         | 12 (9.9) | 1 (0.8) | 30 (100) | 0 (0) | 0 (0) | 0 (0) | <0.001 |
| PCNA             | 3 (2.5)                         | 7 (5.8)                                           | 57 (47.1) | 54 (44.6) | 8 (26.7) | 21 (70) | 1 (3.3) | 0 (0) | <0.001 |
| XIAP             | 20 (16.5)                       | 63 (52.1)                                         | 32 (26.4) | 6 (5.0) | 2 (6.1) | 26 (87.8) | 2 (6.1) | 0 (0) | 0.007 |

Data are shown for negative (−), weakly positive (+), moderately positive (+++), and highly positive (++++) labeling.

p values were obtained by Chi-square test or the Fisher’s exact test; *Fisher’s exact test used with theoretical frequency < 1, italic values: p < 0.05

Positive, and strongly positive expression was seen in 73, 20, and 6 cases, respectively, whereas weakly positive Akt1 expression was seen in 33.3% (10/30) of the normal tissues. CDK6 was expressed in 62.0% (75/121) of the GC cases, and weakly positive, moderately positive, and strongly positive expression was seen in 68, 4, and 4 cases, respectively, whereas weakly positive CDK6 expression was seen in 83.3% (25/30) of the normal tissues. Notch4 was expressed in 95.0% (115/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 64, 48, and 3 cases, respectively, whereas weakly positive Notch4 expression was seen in 73.3% (22/30) of the normal tissues. β-Catenin was expressed in 96.7% (117/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 96, 21, and 0 cases, respectively. β-Catenin was expressed in 93.3% (28/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 27, 1, and 0 cases, respectively. CDK2 was expressed in 56.2% (68/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 55 cases, 12 cases, and 1 case, respectively, whereas no CDK2 immunopositivity was seen in normal tissues. PCNA was expressed in 97.5% (118/121) of the GC cases, and weakly positive, moderately positive, and strongly positive expression in 7, 57, and 54 cases, respectively. PCNA was expressed in 73.3% (22/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 21, 1, and 0 cases, respectively. XIAP was expressed in 97.5% (101/121) of the GC cases, with weakly positive, moderately positive, and strongly positive expression in 63, 32, and 6 cases, respectively. XIAP was expressed in 93.3% (28/30) of the normal tissues, with weakly positive, moderately positive, and strongly positive expression in 26, 2, and 0 cases, respectively. In GC cells, p-PKCα/β2, Akt1, CDK6, Notch4, and PCNA were expressed mainly in the nucleus and the cytoplasm. CDK6 was also expressed in some muscle tissues near GC cells. p-PKCα, CDK2, and XIAP were expressed mainly in the nucleus with low-level expression in the cytoplasm. Of the nine proteins, eight (p-PKCα, p-PKCα/β2, Akt1, CDK6, Notch4, and PCNA) were upregulated in GC tissues when compared to normal tissues (Chi-square or Fisher’s exact tests, p < 0.05; Table 3).

Correlations between protein expression profiles and clinicopathologic parameters of GC

Correlations between protein expression status (negative vs. positive) and clinicopathologic characteristics were determined (summarized in Table 4). Positive p-PKCα/β2 and CDK2 expression in primary GC was associated with higher age (p < 0.05). Increased CDK2 expression also correlated with the presence of vascular/lymphatic invasion (p = 0.014), advanced N stage (p = 0.042), and advanced TNM stage (p = 0.020).

Hierarchical cluster analysis of GC and survival-associated feature selection

Hierarchical cluster analysis was performed with eight protein expression profiles from 121 GC cases. Tumors were separated into two clusters based on protein expression patterns (Fig. 2a). Cluster A contained 20 cases and Cluster B contained 101 cases. Eight of the proteins had much lower (including negative) expression in Cluster A than in Cluster B. Furthermore, Cluster B was subdivided into three subclusters: B11 (35 cases), B12 (15 cases), and B2 (51 cases). Comparison of differences in clinicopathological characteristics among the four (sub)clusters, showed
that Cluster A contained earlier TNM-stage cases than the three B subclusters. Cluster B2 contained more cases with vascular/lymphatic invasion than Cluster A. Kaplan–Meier analysis revealed that Cluster A cases had better survival than cases in Clusters B11, B12, and B2 (p = 0.006; Fig. 2b). Multivariate Cox proportional hazard regression analysis of age, tumor size, histologic differentiation, vascular/lymphatic invasion, TNM stage, and expression of the eight proteins (Cluster A vs. Cluster B) showed that expression of the eight proteins was an independent prognostic indicator of survival (hazard ratio, 5.822; 95% confidence interval, 2.317–14.625; p < 0.001). In addition, age at surgery, tumor size, and TNM stage were also independent prognostic indicators of survival with hazard ratios of 1.914 (95%
confidence interval, 1.186−3.089; p = 0.008), 1.989 (95% confidence interval, 1.175−3.367; p = 0.01), and 1.961 (95% confidence interval, 1.294−2.971; p = 0.002), respectively.

Feature selection was performed with the Kaplan–Meier method (univariate analysis) to identify protein expression profiles associated with survival. Overall survival was worse in cases with CDK2, Akt1, XIAP, Notch4, and p-PKCα/β2 than in cases without immunopositivity for these proteins (log-rank test: p = 0.014, 0.026, 0.042, 0.011, and <0.001, respectively; Fig. 3).

After feature selection, further hierarchical cluster analysis of 121 cases and five survival-associated proteins (CDK2, Akt1, XIAP, Notch4, and p-PKCα/β2) segregated the cases into Cluster 1 (53 cases) and Cluster 2 (68 cases) (Fig. 4a). Univariate analysis performed to determine whether these clusters were indicative of clinically distinct subgroups showed that Cluster 2 cases had poorer prognoses than Cluster 1 cases (p = 0.02; Fig. 4b). Multivariate analysis revealed that this classification (Cluster 1 or 2) was an independent prognostic indicator of survival (hazard ratio, 2.370; 95% confidence interval, 1.447−3.879; p = 0.001).

Establishment of a risk model to predict prognoses of GC patients

Kaplan–Meier analysis (univariate) performed to identify clinicopathological variables associated with GC prognosis indicated that age at surgery, tumor size, T stage, N stage, TNM stage, vascular/lymphatic invasion, and histologic differentiation correlated with overall survival (p < 0.05; Fig. 5). To exclude redundant variables, five proteins (CDK2, AKT1, XIAP, Notch4, and p-PKCα/β2) and five clinicopathological variables (age of surgery, tumor size, TNM stage, vascular/lymphatic invasion, and histologic differentiation) were included in a PCA analysis to extract features. T stage and N stage were excluded from the analysis because they are encompassed in the TNM stage variable. The proteins and clinicopathological variables were considered categorical covariates with corresponding categories: protein expression (immunonegative = 0, immunopositive = 1); gender (female = 0, male = 1); age (≤60 = 0, >60 = 1); tumor size (≤5 = 0, >5 = 1); histologic differentiation (moderate = 0, poor = 1); vascular/lymphatic invasion (absent = 0, present = 1); TNM stage (I = 0, II = 1, III = 2, IV = 3). The code “0” was assigned to the reference category. The Kaiser–Meyer–Olkin measure of sampling adequacy was 0.602 and the significance level (p value) for Bartlett’s Test of Sphericity was <0.001, thus the data were deemed suitable for analysis.

Four factors (PC 1–4) arose from our analysis of PCs with eigenvalues >1.0 in the PCA. The contributing rate of the cumulative sums of the squares was 65.16%. PC loadings for each of the variables are shown in Table 5. PC 1 was heavily loaded with the Notch4, p-PKCα/β2, XIAP, CDK2, and Akt1 variables and termed the protein factor. PC 2 was heavily loaded with the TNM stage and vascular/lymphatic invasion variables and was termed the pathological factor. PC 3 was heavily loaded with the age and tumor size variables and was termed the clinical factor. PC 4 was heavily loaded with the histologic differentiation variable. PC scores (calculated in SPSS) indicated that each of these four factors was independent of the others.

Because PC 1 was a five-protein factor, we established a risk score model based on the five proteins to predict GC prognosis. Risk scores were calculated on the basis of protein expression status (immunonegative/immunopositive) and the corresponding regression coefficients from univariate Cox proportion hazard regression analysis. Risk scores for patients were calculated by multiplying the regression coefficient of a protein by the protein expression status for each protein and then summing the values. The regression coefficients for Notch4, p-PKCα/β2, XIAP, CDK2, and Akt1 were 3.13, 1.52, 0.74, 0.58, and 0.77, respectively. Therefore, in this study, a risk score = 3.13 × (Notch4) + 1.52 × (p-PKCα/β2) + 0.74 × (XIAP) + 0.58 × (CDK2) + 0.77 × (Akt1). The distribution of risk scores for the 121 patients (range, 0−6.73) is presented in Fig. 6a. Based on the risk score curve, the patients were separated into two groups: low-risk (scores <6.15; 54 cases) and high-risk (scores ≥6.15; 67 cases). Kaplan–Meier analysis revealed that overall survival of patients was worse in the high-risk score group than in the low-risk score group (log-rank test: p = 0.005; Fig. 6b) indicating that the risk score model based on Notch4, p-PKCα/β2, XIAP, CDK2, and Akt1 expression predicts GC prognosis.

To further determine whether the number of immunopositive proteins indicated differential overall survival, we regrouped the patients according to numbers of immunopositive proteins: five immunopositive proteins (6.73; 54 cases), four immunopositive proteins (5.96−6.15; 35 cases), and ≤3 immunopositive proteins (0−5.41; 32 cases). Kaplan–Meier analysis showed that patients with ≤3 immunopositive proteins had better overall survival (log-rank test: p = 0.001), whereas patients with 4 or 5 immunopositive proteins had similar and worse overall survival (Fig. 6c).

TNM stage and vascular/lymphatic invasion were categorical covariates. To improve the prognosis predicting efficiency of PC 2 (TNM stage and vascular/lymphatic invasion), we separated PC scores in PC 2 by median score. Kaplan–Meier analysis indicated that the low-score group (≤ median) had better overall survival than the high-score group (> median) (log-rank test: p = 0.004; Fig. 6d). The PC scores in PC 3 (age and tumor size) were also separated by median score. Kaplan–Meier analysis revealed that the low-score
Fig. 3  Expression of a CDK2, b Akt1, c XIAP, d Notch4, e p-PKCa/β2, f p-PKCa, g PCNA and h CDK6 and their association with overall survival. The five proteins with p < 0.05 were chosen by feature selection using the Kaplan–Meier method. p values were determined by log-rank testing.
group had better overall survival than the high-score group (log-rank test: p = 0.002; Fig. 6e). Thus, PC 2 and PC 3 scores can predict GC prognosis. Histologic differentiation in PC 4 separated GC patients into two natural groups. Patients with poor histologic differentiation had worse overall survival than those with moderate differentiation.

ROC curve analysis AUCs for PCs 1–4 were 0.728, 0.732, 0.630, and 0.599, respectively. The sensitivity/specificity/accuracy of PCs 1–4 were 81.48%/49.2%/63.64%, 76.67%/47.54%/61.98%, 75%/45.90%/60.33%, and 71.08%/50%/64.465, respectively. To obtain a risk score prognostic model with higher sensitivity, specificity, and accuracy, a risk score model (PC combination) based on the five proteins and the five clinicopathological variables from the four PCs was established. The risk score was calculated as follows: risk score = \(3.13 \times \text{Notch4} + 1.52 \times \text{(p-PKCα/β2)} + 0.74 \times \text{(XIAP)} + 0.58 \times \text{(CDK2)} + 0.77 \times \text{(Akt1)} + 0.74 \times \text{(TNM stage)} + 1.20 \times \text{(vascular/lymphatic invasion)} + 0.97 \times \text{(tumor size)} + 0.61 \times \text{(age)} + 0.58 \times \text{(histologic differentiation)}\). The distribution of risk scores for the 121 patients (range, 0.58–11.57) is presented in Fig. 7a. Based on the median score (9.25), the patients were separated into low-score (<9.25; 60 cases) and high-score (≥9.25; 61 cases) groups. Kaplan–Meier analysis revealed that overall survival was worse in the high-score group than in the low-score group (log-rank test: p = 0.005; Fig. 7b). The AUC, sensitivity, specificity, and accuracy were 0.912, 96.72%, 70%, and 83.47% for the PC combination risk model, and these values are higher than the values obtained for the four individual PCs (p < 0.001). Thus, the PC combination risk score model predicted the prognosis of GC patients better than the four PCs (Fig. 7c).

Identification of signaling networks associated with survival of patients with GC

Pathway analysis revealed that the proteins analyzed in this study were involved in pathways related to cellular survival and death (eight proteins; p = 1.34 \times 10^{-9}–1.84 \times 10^{-2}), the cell cycle (seven proteins; p = 7.40 \times 10^{-9}–1.66 \times 10^{-2}), cell development (eight proteins; p = 8.33 \times 10^{-9}–1.58 \times 10^{-2}), cell growth and proliferation (eight proteins; p = 8.33 \times 10^{-9}–1.58 \times 10^{-2}), and DNA replication, recombination, and repair (four proteins; p = 1.02 \times 10^{-6}–1.66 \times 10^{-2}). Additionally, pathway analysis in the diseases and disorders
Fig. 5 Univariate Kaplan–Meier analysis of clinicopathological variables associated with the prognosis of GC patients, including a Age at surgery, b tumor size, c Vascular/lymphatic invasion, d Histologic differentiation, e N stage, f T stage and g TNM stage. p values were determined by log-rank testing.
category showed that all eight of the proteins studied were related to cancer \( (p = 3.00 \times 10^{-8} - 1.80 \times 10^{-3}) \), and seven of the proteins associated with metabolic disease \( (p = 6.47 \times 10^{-8} - 1.10 \times 10^{-2}) \). IPA results revealed that the eight proteins evaluated in this study are involved in several canonical signaling pathways, including molecular mechanisms of cancer \( (p = 1.56 \times 10^{-9}) \), HER-2 signaling \( (p = 1.97 \times 10^{-8}) \), gloma signaling \( (p = 4.66 \times 10^{-8}) \), HGF signaling \( (p = 7.01 \times 10^{-8}) \), MAPK signaling \( (p = 1.31 \times 10^{-6}) \), ErB4 signaling \( (p = 7.02 \times 10^{-6}) \), IL-3 signaling \( (p = 3.17 \times 10^{-6}) \), VEGF signaling \( (p = 6.28 \times 10^{-6}) \), p53 signaling \( (p = 8.4 \times 10^{-6}) \), 14-3-3-mediated signaling \( (p = 1.35 \times 10^{-5}) \), p70S6K signaling \( (p = 1.47 \times 10^{-5}) \), mTOR signaling \( (p = 5.45 \times 10^{-5}) \), EGF signaling \( (p = 2.59 \times 10^{-4}) \), cell cycle G1/S checkpoint regulation \( (p = 3.28 \times 10^{-4}) \), ERK/MAPK signaling \( (p = 2.81 \times 10^{-3}) \), and JAK/Stat signaling \( (p = 3.13 \times 10^{-2}) \); Fig. 8a).

Two networks with scores of 23 and 0 were identified by IPA; the former was selected for further analysis. In this network, Akt, CDK2, PKC, caspase, ERK1/2, and cyclin D interacted closely with additional protein signals (Fig. 8b). Upstream analysis of the IPA network detected 525 upstream regulators of the eight proteins, including plant extracts, chemical medicines, microRNAs, transcriptional regulators, kinases, and cytokines. The most significant upstream regulators included embelin (CDK2, CDK6, XIAP; \( p = 4.73 \times 10^{-9} \)), butyric acid (CDK2, CDK6, PCNA, PRKCB, XIAP; \( p = 1.06 \times 10^{-7} \)), silibinin (CDK2, CDK6, XIAP; \( p = 5.19 \times 10^{-7} \)), silicon phthalocyanine (CDK2, CDK6; \( p = 1.34 \times 10^{-6} \)), ingenol mebutate (PRKCA, PRKCB; \( p = 1.34 \times 10^{-6} \)), rolterlin (CDK6, PCNA, XIAP; \( p = 1.41 \times 10^{-6} \)), methyselenic acid (AKT1, CDK2, PCNA, PRKCA; \( p = 1.41 \times 10^{-6} \)), and resveratrol (CDK2, CDK6, PCNA, XIAP; \( p = 1.48 \times 10^{-6} \)). Overall, PCNA, PRKCB, CDK6, CDK2, AKT1, PRKCA, and XIAP were regulated by 4, 2, 6, 5, 1, 2, and 5 upstream regulators, respectively (Fig. 8c).

### Discussion

In this study, to reduce the limitations to clinical application, we used the tissue microarray method on formalin-fixed specimens to evaluate the expression of nine proteins that we identified in a previous PPA study [1] in 121 primary GC tissues and 30 normal gastric tissues. The results showed that all of the nine proteins were expressed in primary GC tissues and eight of the proteins (all except CDK2) were expressed in normal gastric tissues. Additionally, eight of the proteins were upregulated in GC tissues, in accordance with our previous findings [1].

Hierarchical clustering of immunolabeling data from tissue microarrays of 121 formalin-fixed GC samples with nine GC-associated antibodies yielded patient clusters based on protein expression patterns. The patients in Cluster A (20 cases) had better survival than patients in Cluster B11 (35 cases), Cluster B12 (15 cases), and Cluster B2 (51 cases) \( (p = 0.006) \).

Feature selection based on Kaplan–Meier survival analysis yielded Cluster 1 (53 cases) and Cluster 2 (68 cases), which had distinct clinicopathologic features and patient outcomes, with Cluster 2 being associated with poorer prognoses than Cluster 1. Examination of subsequently developed risk score models established to predict clinical outcomes indicated that the PC combination risk model based on five proteins and five clinicopathological variables was clinically relevant and useful for guiding medical treatment. For example, aggressive chemotherapy may be recommended for patients with high-risk scores in this model to improve survival.

We correlated the five proteins obtained from feature selection with clinicopathologic characteristics. Given the generally long delays from tumorigenesis to diagnosis, protein markers would enable earlier diagnoses. Currently, GC is diagnosed based on symptoms, patients’ knowledge of the disease, and the overall medical condition of the patient. Age is also a major factor in GC diagnosis [26]. In our study, the expression levels of p-PKCa/β2 and CDK2 were higher in patients > 60 years old than in younger patients. In addition to age, depth of invasion can be considered a prognostic factor and an indicator of GC progression. Previous studies have shown that vascular/lymphatic invasion status correlates with GC progression [27, 28]. This study showed that upregulation of CDK2 correlates with vascular/lymphatic invasion.

---

**Table 5 Component matrix of variables associated with gastric cancer prognosis**

| Variables                     | Principal components (PC) |
|-------------------------------|----------------------------|
|                               | 1      | 2      | 3      | 4      |
| Notch4                        | 0.798  | 0.128  | 0.0019 | −0.200 |
| p-PKCα/β2                     | 0.726  | −0.071 | 0.353  | 0.107  |
| XIAP                          | 0.652  | 0.048  | −0.371 | −0.128 |
| CDK2                          | 0.563  | −0.408 | 0.888  | 0.279  |
| AKT1                          | 0.532  | −0.059 | 0.448  | −0.013 |
| TNM staging                   | 0.029  | 0.902  | −0.069 | 0.095  |
| Vascular/lymphatic invasion   | −0.013 | 0.873  | 0.047  | 0.134  |
| Age                           | 0.101  | −0.103 | 0.680  | 0.065  |
| Tumor size                    | −0.060 | 0.383  | 0.598  | −0.324 |
| Histologic differentiation    | −0.096 | 0.210  | −0.020 | 0.867  |

Extraction methods: Principal components analysis. Italic values: the variables in different PCs.
CDK2 expression also correlated with N stage and TNM stage, suggesting that CDK2 may play an important role in GC progression, invasion, and metastasis.

Pathway analysis showed that eight of the proteins studied are involved in cellular signaling (p-PKCα and p-PKCα/β2), cell survival and apoptosis (Akt and
XIAP), the cell cycle (CDK6 and CDK2), cell differentiation (Notch4), and cell proliferation (PCNA). A deregulated cell cycle is a fundamental aspect of cancer. Normal cells only proliferate in response to mitogenic or developmental signals, whereas cancer cells proliferate unchecked [29]. In addition, upregulation of PCNA, Akt, and CDK2 has been associated with GC [30–32].
Pathway analysis revealed that the proteins evaluated in this study are involved in several canonical signaling pathways, including HER-2 signaling, MAPK signaling, VEGF signaling, and p53 signaling. It has been suggested that HER-2 expression is a prognostic indicator of GC [33]. MAPK signaling mediates many biological events, such as cell proliferation, differentiation, apoptosis, migration, and invasion in various human cancers, including GC [34, 35]. VEGF is a potent angiogenic factor that has been implicated in tumor-induced angiogenesis, which has been shown to be related to GC development and prognosis [36]. p53 is a transcription factor that regulates a complex signal transduction network referred to as the p53 pathway. The p53 tumor suppressor protein plays a critical role in protection from tumor progression by inducing apoptosis or cell cycle arrest [37]. Thus, we speculate that the proteins evaluated in this study are involved in GC progression and prognosis via these pathways.

Conclusion
In this study, tissues from 121 GC cases were immuno-labeled with nine tumor-associated antibodies in tissue microarrays. Hierarchical cluster analysis based on eight upregulated proteins revealed two clusters with different clinico-pathologic features and prognoses. Kaplan–Meier method-based feature selection revealed five proteins that correlated strongly with overall survival suggesting that a risk score model including these proteins could predict the prognoses of patients with GC. These proteins have been shown to be involved in cancer-related signaling pathways. Future studies will focus on elucidating the roles of these proteins in GC.

Abbreviations
GC: gastric cancer; PPA: protein pathway array; P: phosphorylated; PCNA: proliferating cell nuclear antigen; CDK: cyclin-dependent kinase; XIAP: X-linked inhibitor of apoptosis protein; PKC: protein kinase C; TNM: tumor-node-metastasis; H&E: hematoxylin and eosin; PBS: phosphate-buffered saline; IPA: ingenuity pathway analysis; PCA: principal component analysis.

Acknowledgements
We thank the Department of Pathology of the First Hospital of Jilin University for technical support in preparing the samples.

Authors’ contributions
JS, DGW, and WL conceived and designed the study. WL, YC, and JPY performed the experiments. WL and XS analyzed the data. JS and DGW performed the surgery. JPY and XS prepared the samples. All authors read and approved the final manuscript.

Funding
This research was funded by grants from the National Natural Science Foundation of China (No. 81373295 and No. 81402374) and the Excellent Young Foundation of Jilin Scientific and Technological Development Program (201705200022JH).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study was reviewed and approved by the Institution Ethical Review Board of The First Hospital of Jilin University (No. 2014-087).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin, China. 2. Jilin Province Key Laboratory of Bioinformatics for Gastrointestinal Tumor, Changchun, Jilin, China. 3. Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA.

Received: 21 November 2018 Accepted: 1 August 2019
Published online: 09 August 2019

References
1. Wang D, Ye F, Sun Y, Li W, Liu H, Jiang J, et al. Protein signatures for classification and prognosis of gastric cancer a signaling pathway-based approach. Am J Pathol. 2011;179(4):1657–66.
2. Chen W, Zheng R, Zuo T, Zheng H, Zhang S, He J. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 2016;28(1):1.
3. Wadhwa R, Taketa T, Sudo K, Blum MA, Ajani JA. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013;42(2):359–69.
4. Chen K, Xu XW, Zhang RC, Pan Y, Wu D, Mou YP. Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer. World J Gastroenterol. 2013;19(32):5365–76.
5. Pretz JL, Wu JY, Mamont HJ, Kachnic LA, Hong TS. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. Surg Oncol Clin N Am. 2013;22(3):511–24.
6. Ming-Ming T, Wang CS, Chung-Ying T, Huang HW, Chi HC, Lin YH, et al. Potential diagnostic, prognostic and therapeutic targets of microRNAs in human gastric cancer. Int J Mol Sci. 2016;17(6):945.
7. Muto M. Treatment of gastric cancer. World J Gastroenterol. 2014;10(7):729–35.
8. Oba K, Paolotti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer. 2013;49(7):1565–77.
9. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2010;95(5):385–92.
10. Lauren P. The two histological main types of gastric carcinoma, an attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64(1):31–49.
11. Ming SC. Gastric carcinoma: a pathobiological classification. Cancer. 1977;39(6):2475–85.
12. Goveki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut. 1992;33(5):606–12.
13. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park DJ, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res. 2007;13(14):4154–63.
14. Liu J, Deng N, Xu Q, Sun L, Tu H, Wang Z, et al. Polymorphisms of multiple genes involved in NER pathway predict prognosis of gastric cancer. Oncotarget. 2016;7(30):48130–42.
15. Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer. 2015;75(56):1410–7.
16. Gabbett HE, Muller W, Schneders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 2015;76(5):720–6.
17. Utsumo-Niwa T, Yu Z, Sakamoto H, Kitamura H, Hokue S, Aiko T, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas:
its relationship with the prognosis of the patients. Clin Cancer Res. 1998;4(11):2605.
18. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer. 2015;76(4):941–53.
19. Feakins RM, Nickolls CD, Bidd H, Walton SJ. Abnormal expression of p16, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol. 2003;34(12):1276–82.
20. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200(1):39–46.
21. Jacquemier J, Ginestier C, Rougemon J, Bardou VJ, Charafe-Jauffret E, Geneix J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Can Res. 2005;65(3):767–79.
22. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161(4):1223.
23. Rosen DG, Huang C, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004;17(7):790–7.
24. Fehon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20(9):1453–4.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863–8.
26. Lee HI, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer. 2002;25(1):77–82.
27. Bu Z, Zheng Z, Li Z, Zhang L, Wu A, Wu X, et al. Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients. Tumor Biol. 2013;34(2):1005–12.
28. Kusano T, Shiraishi N, Shioshita H, Etoh T, Inomata M, Kitano S. Poor prognosis of advanced gastric cancer with metastatic suprapancreatic lymph nodes. Ann Surg Oncol. 2013;20(7):2290–5.
29. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):360–81.
30. Li N, Deng W, Ma J, Wei B, Guo K, Shen W, et al. Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol. 2015;32(1):1–9.
31. Liang G, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E, cyclin dependent kinase 2 and p57 (KIP2) in human gastric cancer. Chin Med J. 2003;116(1):20–3.
32. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seo DI, et al. Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 2003;94(12):1066–73.
33. Ross JS, Mckenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19(5):554–68.
34. Meng X, Zhang S. MAPK cascades in plant disease resistance signaling. Annu Rev Phytopathol. 2013;51(1):243–66.
35. Li P, Xue W-J, Feng Y, Mao Q-S. Long non-coding RNA CASC2 suppresses the proliferation of gastric cancer cells by regulating the MAPK signaling pathway. Am J Transl Res. 2016;8(8):3522.
36. Kakeji Y, Koga T, Sumiyoshi Y, Shibahara K, Oda S, Maehara Y, et al. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res. 2002;21(1):125–9.
37. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.